Basit öğe kaydını göster

dc.contributor.authorSahin, H.
dc.contributor.authorAyhan, S.
dc.contributor.authorSari, M.E.
dc.contributor.authorTohma, V.A.
dc.contributor.authorYaman, S.
dc.contributor.authorYalcin, I.
dc.contributor.authorCandar, T.
dc.contributor.authorGungor, T.
dc.date.accessioned2020-12-25T07:27:15Z
dc.date.available2020-12-25T07:27:15Z
dc.date.issued2019
dc.identifier.issn0392-2936en_US
dc.identifier.urihttp://hdl.handle.net/11727/5193
dc.description.abstractObjective: To investigate the importance of ischemia modified albumin (IMA) in the diagnosis and evaluation of endometrial carcinoma. Material and Methods: Serum IMA levels of patients with and without endometrial cancer were measured by the calorimetric assay technique and their absorbance units were compared. Results: A total of 128 women were included in the study; 64 of these women were endometrial cancer patients and 64 of them were in the control group. The median age for these groups were 58.5 and 56 years, respectively. There was no significant difference in terms of age, body mass index, and serum albumin levels between the groups (p > 0.05). In the endometrial cancer group, the median serum IMA level was 0.489 (0.401-0.611), while in the control group the median serum IMA level was 0.490 (0.407-0.589). There was no significant difference between these two groups (p = 0.467). In the type 1 endometrial cancer group, the median serum IMA level was 0.452 (0.401-0.590), while in the type 2 endometrial cancer group the median serum IMA level was 0.559 (0.462-0.611) A significant difference was found between types 1 and 2 endometrial cancers (p < 0.001). Conclusions: The IMA level does not appear to be an additional predictive marker of preoperative diagnosis and evaluation of endometrioid type endometrial cancer when compared to the healthy control group; on the other hand, IMA may be a marker for the detection of type 2 endometrium cancers when compared with type 1 endometrium tumors. However, further randomized controlled trials are required to make a comparison between type1 and type2 endometrial cancers.en_US
dc.language.isoengen_US
dc.relation.isversionof10.12892/ejgo4622.2019en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial canceren_US
dc.subjectEndometrioid histopathologen_US
dc.subjectIschemia modified albumin (IMA)en_US
dc.titleSerum ischemia modified albumin and endometrial cancer: a prospective case-control studyen_US
dc.typearticleen_US
dc.relation.journalEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGYen_US
dc.identifier.volume40en_US
dc.identifier.issue3en_US
dc.identifier.startpage384en_US
dc.identifier.endpage388en_US
dc.identifier.wos000474852400006en_US
dc.identifier.scopus2-s2.0-85072205693en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster